MECHELEN, BELGIUM--(Marketwire - December 18, 2008) - Mechelen, Belgium; 18 December 2008 - Galapagos NV (Euronext: GLPG) announced today that its service division BioFocus DPI has extended its longstanding drug discovery collaboration with Amgen through 2009 and 2010. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen’s discovery programs. Under the terms of the extended agreement, Galapagos will receive EUR 2.0 M ($2.55 M) in research fees per year for two years. Additionally, Galapagos is eligible to receive compensation in the form of access fees and success-based milestones.
